ABSTRACT
Fundamentos: El cáncer de mama representa la primera causa de mortalidad prematura en las mujeres de la provincia de Toledo. El objetivo es conocer el estadío al diagnóstico para cada grupo de edad y la supervivencia relativa (SR) del cáncer de mama a los 5 años, enel Área de Toledo-Centro y Mancha de los tumores diagnosticados durante 1997-1999. Métodos: Se utilizó la información del Registro Poblacional de Cáncer de Toledo. Se incluyó a 366 mujeres con tumores clasificados por estadio y grupo de edad (en función de su inclusión en el programa de detección precoz de cáncer de mama, <45, 45-64 y >64). La SR e intervalo de confianza al 95% (IC) fueron calculados mediante el método de Hakulinen utilizando la aplicación WAERS. Resultados: La SR global fue 78,4% (IC: 73,6-83,6), siendo 93,3% (IC: 87,0-99,4) en < 45 años; 87,6% (IC: 81,5-94,1) para el grupo de 45-64 años; y 75,4% (IC: 65,3-86,9) en > 64 años. La SR fue 99,3% (IC: 94,4-104,5) para tumores localizados; 81,9% (IC: 74,0-90,8) para tumores con afectación ganglionar; y 20,1% (IC: 9,7-41,6) para tumores con metástasis. Al diagnóstico, el 52,3% de los tumores en < 45 años presentaba afectación ganglionar; el 14,8% en > 64 años presentaba metástasis. Conclusiones: La SR es similar a la media del estudio EUROCARE-4. Estos resultados son un punto de partida para valorar, mediante el seguimiento de estos indicadores, el impacto de las actividades de detección precoz y terapéuticas en la SR del cáncer de mama en nuestra área(AU)
Background: To determine 5-year relative survival (5 year-RS) of breast cancer cases in Toledo-Centro and Mancha area by age group and stage at diagnosis during the period 1997-1999. Methods: Data of incident breast cancer was obtained from Toledo Cancer Registry. A total of 366 tumours were included, classified by stage and age group (according to their inclusion in the screening program for breast cancer, <45, 45-64 and> 64). The 5 year-RS and its 95% confidence interval (CI) were calculated using the Hakulinen method through the web-based application WAERS. Results: Global 5year-RS was 78.4% (CI 73.6-83.6), being 93.3% (CI 87.0-99.4) in <45 years, 87.6% (CI 81.5-94.1) for the 4564 years age group and 75.4% (CI 65.3- 86.9) in > 64 years. The 5year-RS was 99.3% (CI: 94.4-104.5) for tumours with local stage, 81.9% (CI 74.0-90.8) for those tumours spread to lymph nodes and 20.1% (CI 9.7-41.6) for tumours with metastasis. At the time of diagnosis, 52.3% of tumours in women under age 45 had spread to lymph nodes, while 14.8% of women over 64 had distant metastasis. Conclusions: The 5year-RS is similar to the European average of EUROCARE-4 study. These results are a first step to assess, through the monitoring of these indicators, the impact of screening activities and therapeutic improvements in the 5year-RS of breast cancer in our area(AU)
Subject(s)
Humans , Female , Adult , Middle Aged , Survival , Breast Neoplasms/epidemiology , Early Diagnosis , Neoplasm Staging/statistics & numerical data , Neoplasm Staging/trends , Neoplasm Staging/classification , Neoplasm Staging/mortality , Neoplasm Staging , Spain/epidemiology , Primary Health Care/standards , Primary Health Care , Indicators of Quality of LifeABSTRACT
BACKGROUND: To determine 5-year relative survival (5 year-RS) of breast cancer cases in Toledo-Centro and Mancha area by age group and stage at diagnosis during the period 1997-1999. METHODS: Data of incident breast cancer was obtained from Toledo Cancer Registry. A total of 366 tumours were included, classified by stage and age group (according to their inclusion in the screening program for breast cancer, < 45, 45-64 and> 64). The 5 year-RS and its 95% confidence interval (CI) were calculated using the Hakulinen method through the web-based application WAERS. RESULTS: Global 5 year-RS was 78.4% (CI 73.6-83.6), being 93.3% (CI 87.0-99.4) in < 45 years, 87.6% (CI 81.5-94.1) for the 45-64 years age group and 75.4% (CI 65.3-86.9) in > 64 years. The 5 year-RS was 99.3% (CI: 94.4-104.5) for tumours with local stage, 81.9% (CI 74.0-90.8) for those tumours spread to lymph nodes and 20.1% (CI 9.7-41.6) for tumours with metastasis. At the time of diagnosis, 52.3% of tumours in women under age 45 had spread to lymph nodes, while 14.8% of women over 64 had distant metastasis. CONCLUSIONS: The 5 year-RS is similar to the European average of EUROCARE-4 study. These results are a first step to assess, through the monitoring of these indicators, the impact of screening activities and therapeutic improvements in the 5 year-RS of breast cancer in our area.
